QuidelOrtho Corporation
NASDAQ:QDELMedical - Instruments & Supplies
+$0.09 today
- Market cap
- $656.62M
- Beta
- 0.76
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$17.76
Volume 2.13M
Average 2.35M
QDEL Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
QuidelOrtho CorporationNASDAQ: QDEL
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses remains negative
Q1 FY2026 other income / expenses was -$52.1M, compared with -$41.4M a year earlier. Trailing-twelve-month other income / expenses was -$199.2M.
Context
- Other income / expenses amounted to 6.9% of revenue in FY2025, up 0.8 pp from a year earlier.
- Other income / expenses grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$52.1M or moves back toward the trailing-twelve-month quarterly average of -$49.8M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (188.5M) USD
- Year-over-year change
- -10.5%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | (188.5M) | -10.5% |
| FY2024 | 2024-12-29 | (170.6M) | -1.4% |
| FY2023 | 2023-12-31 | (168.2M) | -56.0% |
| FY2022 | 2023-01-01 | (107.8M) | -1791.2% |
| FY2021 | 2021-12-31 | (5.7M) | — |
Other Income / Expenses vs competitors
How QDEL compares with its peers on the latest reported figures
- QDEL's LTM Mar 2026 other income / expenses of -$199.2M is the 7th highest of the 9 companies compared; the peer median is -$26.05M.
- Its year-over-year change of -16.4% is the 4th highest of 9, against a peer median of -34.4%.
- Other income / expenses amounts to 7.5% of revenue for QDEL, versus a peer median of 3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $115.4M | -49.1% | — | 4.5% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $717.46K | +90.1% | — | 7.4% |
| LTM Mar 2026 | -$208K | -104.2% | — | 0.2% | |
| LTM Dec 2025 | -$25.97M | -171.5% | — | 59.2% | |
| LTM Mar 2026 | -$26.13M | -117.8% | — | 4.5% | |
| LTM Jul 2026 | -$98.08M | -19.7% | — | 3.4% | |
| LTM Mar 2026 | -$199.2M | -16.4% | — | 7.5% | |
| LTM Sep 2026 | -$229M | -12.3% | — | 1.9% | |
| LTM Sep 2026 | -$646M | +34.1% | — | 1.4% | |
| Peer median (excluding QDEL) | -$26.05M | -34.4% | — | 3.9% | |
Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.7B | 3.27B | 3B | 2.78B | 2.73B |
| Cost of Revenue | 420.3M | 1.33B | 1.5B | 1.5B | 1.46B |
| Gross Profit | 1.28B | 1.94B | 1.5B | 1.29B | 1.27B |
| Gross Margin | 75.3% | 59.3% | 49.9% | 46.2% | 46.7% |
| Research & Development | 95.7M | 187.9M | 246.8M | 218.7M | 186.2M |
| Selling, General & Admin | 239.6M | 621M | 763.2M | 766.8M | 746.3M |
| Operating Expenses | 372.3M | 1.09B | 1.36B | 3.25B | 2.19B |
| Depreciation & Amortization | 52.7M | 283.6M | 457.2M | 453.4M | 442M |
| EBITDA | 953.3M | 1.09B | 607M | (1.49B) | (488.1M) |
| EBITDA Margin | 56.1% | 33.5% | 20.2% | -53.5% | -17.9% |
| Operating Income | 906M | 843.7M | 139.1M | (1.96B) | (919.2M) |
| Operating Margin | 53.3% | 25.8% | 4.6% | -70.5% | -33.7% |
| Interest Income | 300K | 1.3M | 2.2M | 0 | 0 |
| Interest Expense | 700K | 74.5M | 178.9M | 188.3M | 177.6M |
| Other Income / Expenses | (5.7M) | (107.8M) | (168.2M) | (170.6M) | (188.5M) |
| Income Before Tax | 900.3M | 735.9M | (29.1M) | (2.13B) | (1.11B) |
| Pre-Tax Margin | 53.0% | 22.5% | -1.0% | -76.6% | -40.6% |
| Income Tax Expense | 196.1M | 187.2M | (19M) | (79.5M) | 24.1M |
| Net Income | 704.2M | 548.7M | (10.1M) | (2.05B) | (1.13B) |
| Net Margin | 41.5% | 16.8% | -0.3% | -73.7% | -41.5% |
| EPS (Basic) | 16.74 | 9.66 | (0.15) | (30.54) | (16.69) |
| EPS (Diluted) | 16.43 | 9.56 | (0.15) | (30.54) | (16.69) |
| Weighted Avg Shares | 42.08M | 56.8M | 66.8M | 67.2M | 67.8M |
| Weighted Avg Shares (Diluted) | 42.87M | 57.4M | 66.8M | 67.2M | 67.8M |
QuidelOrtho Corporation
NASDAQ:QDEL
Intrinsic Alpha fair value
Locked
Current Price
$9.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.